Comparative Pharmacology
Head-to-head clinical analysis: SALAGEN versus VUITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SALAGEN versus VUITY.
SALAGEN vs VUITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pilocarpine is a cholinergic parasympathomimetic agent that acts as a muscarinic receptor agonist, stimulating exocrine gland secretion (salivary, sweat, lacrimal, gastric, pancreatic) and smooth muscle contraction.
VUITY (pilocarpine hydrochloride ophthalmic solution) 1.25% is a muscarinic receptor agonist. It induces miosis by contracting the iris sphincter muscle, increasing the eye's depth of focus and improving near visual acuity. It acts via the ciliary muscle to reduce the diameter of the pupil, creating a pinhole effect that enhances depth of focus.
5 mg orally three times daily.
One drop of VUITY (pilocarpine 1.25% ophthalmic solution) instilled into each eye three times daily at approximately 6-8 hour intervals.
None Documented
None Documented
Terminal elimination half-life is 5-6 hours in patients with normal renal function; may be prolonged to 6-8 hours in elderly or those with hepatic impairment.
Terminal half-life: 134 hours (range 110-170 hours). Clinical context: allows once-weekly dosing; steady-state achieved after 2-3 months.
Renal excretion of unchanged drug and metabolites: 80-90% in urine, with approximately 20% unchanged; biliary/fecal excretion accounts for less than 5%.
Primarily via hepatic metabolism; inactive metabolites excreted in urine (approximately 90%) and feces (approximately 10%).
Category C
Category C
Cholinergic Agonist
Cholinergic Agonist